Sep 13, 2022 / 03:00PM GMT
Unidentified Analyst
Good morning, everyone, and welcome to the second day of our 24th Annual Global Investment Conference. My name is [Farhad King]. I'm an equity research associate at H.C. Wainwright. It's my pleasure to introduce our next speakers of today. From Galectin Therapeutics, please welcome Pol Boudes, Chief Medical Officer; and Joel Lewis, CEO.
Joel Lewis - Galectin Therapeutics Inc. - CEO
Thank you.
Pol Boudes - Galectin Therapeutics Inc. - Chief Medical Officer
Thank you very much. Thank you also for inviting us to the H.C. W. Conference. So I'm going to present -- I'll start first with our forward-looking statements and a little bit of talk about NASH cirrhosis, which is a silent killer.
People talk a lot about -- I'm going to give you some numbers. People talk about fatty liver. So there is an estimated 100 million Americans with fatty liver. And of those, that's a number you don't really hear that frequently. 5 million are estimated to progress to NASH cirrhosis.
When you have cirrhosis of
Galectin Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers